Compare Citius Pharmaceuticals Inc (CTXR) vs Flux Power Holdings Inc (FLUX) Price & Performance

CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.

The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.

FLUX trades at $0.47, down 3.96% today, with bearish technical signals from moving averages. The company reported Q4 2026 revenue of $8.2M, beating expectations, but posted a net loss of $6.67M for 2025. Recent news highlights a rejected acquisition proposal from Solidion Technology. Despite negative profitability metrics, all six covering analysts maintain Buy ratings.

FLUX faces significant execution risks with negative margins and cash flow challenges, but analyst consensus remains bullish. The stock's current valuation at 0.22 P/S suggests potential upside if operational improvements materialize. Key risks include sustained losses and competitive pressures in the energy storage sector.